Denmark reassesses rejection of Novartis cancer combination to include more exceptions

The Danish Medicines Council has re-evaluated a combination treatment application from Novartis that it rejected in 2018. The answer is still no, but there are now more exceptions attached.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Members of the Danish Medicines Council have said no to an application from Novartis, which was hoping to see drugs Tafinlar (dabrafenib) and Mekinist (trametinib) approved as a as standard combination treatment for stage III melanoma with the BRAF V600 mutation, the council reports on its website.

The original filing is dated Sep. 20, 2018, and the council adopted its final opinion few months later. Back then, the council did not recommend the combination treatment, but has now cracked the door open slightly.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs